Recurrence after surgery in patients with NSCLC
作者： Hidetaka Uramoto , Fumihiro Tanaka
DOI: 10.3978/J.ISSN.2218-6751.2013.12.05
关键词:
摘要: Surgery remains the only potentially curative modality for early-stage non-small cell lung cancer (NSCLC) patients and tissue availability is made possible. However, a proportion of develop recurrence, even after resection. This review discusses superiority surgery, reasons timing pattern identification factors related to current provisions treatment perspectives about surgery with NSCLC.
amegroups.com参考文章(81)
Veli-Matti Kosma, Risto Pirinen, Risto Johansson, Jan Böhm, Tero Leinonen, Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histology and Histopathology. ,vol. 23, pp. 693- 700 ,(2008) , 10.14670/HH-23.693
Chung-Ping Hsu, Sen-Ei Shai, Jiun-Yi Hsia, Chih-Yi Chen, Clinical Significance of Bone Marrow Microinvolvement in Nonsmall Cell Lung Carcinoma: A Long-Term Follow-Up Report Cancer. ,vol. 100, pp. 794- 800 ,(2004) , 10.1002/CNCR.20027
K. S. Albain, R. S. Swann, V. R. Rusch, A. T. Turrisi, F. A. Shepherd, C. J. Smith, D. R. Gandara, D. H. Johnson, M. R. Green, R. C. Miller, Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309) Journal of Clinical Oncology. ,vol. 23, pp. 7014- 7014 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.7014
Takeshi Hanagiri, Hidetaka Uramoto, Kenji Ono, Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC. Anticancer Research. ,vol. 30, pp. 3273- 3278 ,(2010)
Morgan N. Windsor, Peter V. Goldstraw, Rishendran Naidoo, Surgery in 2013 and beyond. Journal of Thoracic Disease. ,vol. 5, ,(2013) , 10.3978/J.ISSN.2072-1439.2013.07.39
Hidetaka Uramoto, Takashi Iwanami, Soichi Oka, Hidehiko Shimokawa, Fumihiro Tanaka, The Expression of Ki-67, but Not Proliferating Cell Nuclear Antigen, Predicts Poor Disease Free Survival in Patients with Adenocarcinoma of the Lung Anticancer Research. ,vol. 31, pp. 4277- 4282 ,(2011)
J. P. van Meerbeeck, G. W. P. M. Kramer, P. E. Y. Van Schil, C. Legrand, E. F. Smit, F. Schramel, V. C. Tjan-Heijnen, B. Biesma, C. Debruyne, N. van Zandwijk, T. A. W. Splinter, G. Giaccone, Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non–Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 99, pp. 442- 450 ,(2007) , 10.1093/JNCI/DJK093
U Pastorino, S Andreola, E Tagliabue, F Pezzella, M Incarbone, G Sozzi, M Buyse, S Menard, M Pierotti, F Rilke, Immunocytochemical markers in stage I lung cancer: relevance to prognosis. Journal of Clinical Oncology. ,vol. 15, pp. 2858- 2865 ,(1997) , 10.1200/JCO.1997.15.8.2858
Ajeet Gajra, Nancy Newman, Gary P. Gamble, Leslie J. Kohman, Stephen L. Graziano, Effect of Number of Lymph Nodes Sampled on Outcome in Patients With Stage I Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 21, pp. 1029- 1034 ,(2003) , 10.1200/JCO.2003.07.010
Felice Pasini, Giuseppe Pelosi, Francesco Valduga, Emilia Durante, Giovanni de Manzoni, Marta Zaninelli, Alberto Terzi, Late events and clinical prognostic factors in stage I non small cell lung cancer Lung Cancer. ,vol. 37, pp. 171- 177 ,(2002) , 10.1016/S0169-5002(02)00040-5